Data cannot be shared publicly at this time because our data contains potentially identifying participant information. The study population is a relatively small cohort of employees at Massachusetts General Hospital (a named institution in the manuscript) enrolled in the ChooseWell 365 RCT during a recent time period. Sharing information on individuals' age, sex, dates, timing of cafeteria purchases, and BMI will compromise participant privacy. Data are available from the Partners Human Research Office/Institutional Review Board at Partners HealthCare (contact located at <https://www.partners.org/Medical-Research/Support-Offices/Human-Research-Committee-IRB/Default.aspx>) for researchers who meet the criteria for access to confidential data.

Introduction {#sec008}
============

Genetics play a role in the development of obesity and cardiometabolic disease \[[@pmed.1003219.ref001]\], yet the influence of genetic risk for obesity on food choice behaviors is not well understood. The heritability of body mass index (BMI) is estimated to range from 47% to 90% \[[@pmed.1003219.ref002]\]. BMI-associated genetic variants, either independently (i.e., *FTO*, *MC4R*) or in aggregate (i.e., in the form of a polygenic risk score \[PRS\]), have also been linked with self-reported eating-related traits and behaviors, including increased appetite, reduced satiety, uncontrolled eating, and emotional eating \[[@pmed.1003219.ref003]--[@pmed.1003219.ref006]\]. Self-reported behaviors, however, are prone to misreporting or social desirability biases \[[@pmed.1003219.ref007]\]. Thus, it remains unclear whether genetic risk for obesity is associated with quality, quantity, or timing of food choices, each of which may mediate the relationship between the risk alleles and obesity.

A genome-wide association study (GWAS) in over 300,000 adult participants identified 97 common independent genetic variants that are associated with BMI \[[@pmed.1003219.ref008]\]. More than half of these 97 variants are enriched for expression in regions of the central nervous system (CNS), including hypothalamus circuits that regulate appetite, whereas the remaining span other tissues with unlikely CNS functions \[[@pmed.1003219.ref008],[@pmed.1003219.ref009]\]. Recently, it was demonstrated that a genome-wide polygenic score (GPS) comprising all 2.1 million common variants across the genome accounted for up to 20% of the variation in BMI \[[@pmed.1003219.ref008]\], and this may provide a more robust score to detect obesity-related associations with dietary behaviors.

Previous large cohort studies have demonstrated that consumption of sugar-sweetened beverages accentuated genetic risk for obesity, whereas consumption of a healthier diet attenuated genetic risk for obesity \[[@pmed.1003219.ref010],[@pmed.1003219.ref011]\]. These studies concluded that genetic risk for obesity is modified by dietary environmental exposures. However, it remains unknown if genetic risk for obesity directly influences food choice behaviors and dietary intake. Obesity-implicated genetic variants may influence eating behaviors and obesity through a range of biological mechanisms that determine taste preferences, satiety, and cognitive and physiological responses to food and food cues \[[@pmed.1003219.ref011]--[@pmed.1003219.ref015]\]. Therefore, genetic predisposition to food choice behaviors may be in the causal pathway between genetic risk and the development of obesity, and genetic variants with CNS and non-CNS functions may contribute differentially to food choice behaviors.

Workplace cafeteria purchasing data provided an opportunity for objective, real-time assessment of employees' food choices. Prior research demonstrated that the healthfulness of workplace food purchases was associated with employees' overall dietary quality and health \[[@pmed.1003219.ref016]\]. We hypothesized that higher obesity genetic risk was associated with food purchasing patterns and self-reported dietary behaviors that contribute to weight gain and obesity.

Therefore, the aim of the current study was examine associations between obesity genetic risk and food choice behaviors using objectively assessed workplace food purchases (quality, quantity, and timing) collected at baseline from a cohort of employees who enrolled in a workplace health-promotion trial \[[@pmed.1003219.ref017]\]. We also assessed whether higher CNS-related obesity genetic risk may be more likely to be associated with food behavioral choices than the non-CNS component.

Methods {#sec009}
=======

This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines ([S1 STROBE](#pmed.1003219.s001){ref-type="supplementary-material"} Checklist).

Setting and participants: "ChooseWell 365" cohort {#sec010}
-------------------------------------------------

This study is a secondary analysis of baseline data collected from participants in the "ChooseWell 365" cohort, a workplace health-promotion study at Massachusetts General Hospital (MGH), prior to the start of the health-promotion intervention randomized control trial \[[@pmed.1003219.ref017]\]. MGH is a 999-bed teaching hospital in Boston, MA, with over 27,000 employees, who are 70% female and have a mean age of 41 years. A total of 602 MGH employees (female = 79.4%; mean \[standard deviation\]: age = 43.6 \[12.2\] years; baseline BMI = 28.3 \[6.5\] kg/m^2^) enrolled between September 2016 and February 2018 in the "ChooseWell 365" randomized controlled trial (Clinicaltrials.gov: NCT02660086) testing a workplace intervention to promote healthy food choices and prevent weight gain \[[@pmed.1003219.ref017]\]. Employees were eligible for the trial if they were between 20 and 75 years of age and used their employee badge to purchase cafeteria items at least 4 times per week for at least 6 weeks during a 12-week period prior to recruitment. Additional recruitment criteria have been previously described \[[@pmed.1003219.ref017]\]. Analyses were prospectively planned to test the associations between BMI genetic scores and food choices as outlined in the analysis plan (**[S1 Text](#pmed.1003219.s002){ref-type="supplementary-material"}**). Participants provided written informed consent upon enrollment, and the study protocol was approved by Partners HealthCare Institutional Review Board (\#2015P000135).

The data for the current study are restricted to participants who consented to providing genetic data and who were of European ancestry (restricted to avoid population stratification issues and to be consistent with the GWAS that were discovered in populations of European ancestry). Analyses were conducted using survey and health data collected at a baseline visit prior to the initiation of the parent trial intervention, and cafeteria data were collected retrospectively from the 3 months prior to enrollment. We used 3 months to represent typical and habitual purchases and avoid irregularities due to short-term vacations or work schedule changes. Of the 602 participants, 499 consented to have genotyping, and 397 were of European ancestry and included in the current analysis (**[S1 Fig](#pmed.1003219.s008){ref-type="supplementary-material"}**).

Workplace purchases, anthropometry, and dietary variables {#sec011}
---------------------------------------------------------

During the study period, the hospital campus had 6 on-site food service locations, including 3 full-service cafeterias and 3 smaller cafes (hereafter, all referred to as "cafeterias"). The cafeterias were typically open 5 or 7 days per week and offered breakfast and lunch options in the mornings through afternoons and limited snacks/side and dinner options in the evenings and overnight. More than 1,200 different food items are available over the course of a day, including meals and entrees (e.g., hot prepared meals, prepared sandwiches and salads, and pizza), a large salad bar, snacks, and desserts, as well as hot and cold beverages. All employees in the study paid for cafeteria items by payroll deduction using their employee identification badge, and purchases were tracked using cafeteria sales data \[[@pmed.1003219.ref016]\].

All hospital cafeterias labeled food and beverages with traffic-light labels, as has been described in detail elsewhere \[[@pmed.1003219.ref017],[@pmed.1003219.ref018]\], and this labeling system had been utilized at the hospital since 2010. Briefly, the traffic-light labeling system was designed by hospital nutrition staff and based on the USDA Dietary Guidelines \[[@pmed.1003219.ref019],[@pmed.1003219.ref020]\]. Every item was labeled as red, yellow, or green based on an algorithm that factored in calories, saturated fat content, and nutrient density. A green rating connoted the highest level of healthfulness and a red rating indicated the lowest level (e.g., least healthy). Options were distributed roughly evenly between those labeled green (34%), yellow (37%), or red (29%). The average costs of red, yellow, and green items were comparable for beverages, entrees, and snacks/side items, and items across a range of prices were available in each color category \[[@pmed.1003219.ref016]\].

Participants' baseline purchases were extracted from the hospital's cafeteria sales data for the 3 months prior to their enrollment in the randomized trial. Purchasing data included item type, time and date of purchase, and the traffic-light label color (i.e., red, yellow, green). The quality of workplace food purchases was measured with a Healthy Purchasing Score that reflected the overall healthfulness of an employee's 3-month baseline purchases \[[@pmed.1003219.ref016]\]. The Healthy Purchasing Score was created by weighting purchases of red items to be 0, yellow items to be 0.5, and green items to be 1. This score has been previously validated as a proxy for overall dietary healthfulness using 24-hour dietary recalls \[[@pmed.1003219.ref016]\]. For interpretation purposes in this study, the Healthy Purchasing Score was converted to percentage by multiplying the score by 100 (range, 0%--100% healthy). The quantity of workplace food purchases was measured by the total number of items purchased over 3 months, as well as the number of food and beverage items, separately. Time of day of workplace food purchases was measured by using the time stamp for the purchase data during the 3-month baseline period. The median timing of breakfast purchases (first food purchased between 6 AM and 10 AM) and median time of lunch purchase (first food purchased between 11 AM and 2 PM) were estimated for each participant.

Participants' weight and height were measured by clinical research nursing staff at the baseline visit, and BMI was calculated as weight/height^2^ (kg/m^2^). Participants also completed an online survey that provided self-reported age, sex, meal-skipping habits ("Over the PAST WEEK, on how many days did you SKIP BREAKFAST/ LUNCH/ DINNER for any reason?"; Never, 1--2 days, 3--4 days, 5--6 days, and Every day), and home-prepared meal habits ("Over the PAST WEEK, on how many days did you eat a BREAKFAST/ LUNCH/ DINNER that was prepared at home \[including meals that you bring to work\]?"; Never, 1--2 days, 3--4 days, 5--6 days, and Every day).

Genetic data genotyping, imputation, and quality control {#sec012}
--------------------------------------------------------

DNA was extracted from blood samples collected from 499 participants and genotyped using the Infinium Global Screening (GSA) Array-24 v2.0. Imputation was performed using the Michigan Imputation server with the Haplotype Reference Consortium (HRC, Version r1.1 2016) reference panel for imputation \[[@pmed.1003219.ref021]\]. This HRC panel consists of 64,940 haplotypes of predominantly European ancestry. Haplotype phasing was performed using Eagle v2.3 \[[@pmed.1003219.ref022]\]. Low-quality genetic markers in Hardy-Weinberg disequilibrium (*P* \< 10^−6^), low minor allele frequency (\<0.01), and low call rate (\<98%) were excluded (200,067 genetic markers excluded). Furthermore, samples were tested for low-quality genetic samples with low sample call rate (\<95%) or high heterozygosity rate (\>median + 3\*IQR), but none were excluded.

Participant ancestry was determined using TRACE \[[@pmed.1003219.ref023]\] and the Human Genome Diversity Project (HGDP) \[[@pmed.1003219.ref024]\] as a reference panel. Principal component analysis outliers were determined by using a principal component analysis projection of the study samples onto the HGDP reference samples and were subsequently excluded from analysis (*n* = 100 excluded). To correct for population stratification, we computed principal components of ancestry using TRACE \[[@pmed.1003219.ref023]\] in the subset with genetically European ancestry. Furthermore, sample relatedness was determined using PLINK \[[@pmed.1003219.ref025]\], and subsequently, 1 sample from each detected related pair (pi-hat \> 0.25) was excluded.

Generation of PRSs {#sec013}
------------------

A total of 3 PRSs were generated for each participant from 97 previously identified single nucleotide polymorphisms (SNPs) at the genome-wide significance levels (*P* \< 5 × 10^−8^). The BMI~97~ PRS comprised all 97 previously identified BMI variants \[[@pmed.1003219.ref008]\]. Based on the biological functions of genes in or near the 97 previously identified BMI loci, such as neuronal development process, neurotransmission, hypothalamic expression and regulatory function, and neuronal expression, 54 variants have been previously classified as CNS-related, and 43 variants have been previously classified as non-CNS-related \[[@pmed.1003219.ref008]\]. Accordingly, the BMI~CNS~ PRS and the BMI~non-CNS~ PRS comprised the 54 and 43 non-overlapping BMI variants, respectively \[[@pmed.1003219.ref026]\]. All SNPs had a minor allele frequency \>1% and an imputation quality (minimac *r*~sq~) ≥0.50. We derived the PRSs for each individual participant by summing the number of risk alleles that were each weighted by the allelic effect sizes (β-coefficients) published in the original GWAS meta-analysis with up to 339,224 individuals from 125 studies \[[@pmed.1003219.ref008]\]. Scaling of the individual PRSs was performed to allow interpretation of the effects as a per-1 risk allele increase in the PRS for each trait (division by twice the sum of the β-coefficients and multiplication by twice the square of the SNP count representing the maximum number of risk alleles).

Generation of GPS {#sec014}
-----------------

We generated a BMI GPS for each individual by summing BMI-increasing risk alleles across the genome, each weighted by the beta estimate for that allele from the BMI GWAS meta-analyses \[[@pmed.1003219.ref008]\]. Only SNPs with a minor allele frequency \>1% and an imputation quality (minimac *r*~sq~) ≥0.50 were considered in the GPS. Thus, we included 1,988,363 SNPs after excluding X chromosome variants and, at each site, clumped SNPs based on association *P* value (the variant with the smallest *P* value within a 250-kb range was retained and all those in linkage disequilibrium, *r*^2^ \> 0.1, were removed). Linkage disequilibrium clumping and GPS generation were conducted using PRSice \[[@pmed.1003219.ref027]\], and the best-fit genome-wide BMI GPS based on this cohort's inverse normalized BMI encompassed 64,952 SNPs at *P* value threshold of 0.19. In sensitivity analyses, we also generated BMI GPS based on other *P* value thresholds (1.00 \[SNPs *n* = 126,161\], 0.50 \[SNPs *n* = 98,995\], and 0.25 \[SNPs *n* = 73,412\]) and re-ran analyses.

Statistical analysis {#sec015}
--------------------

Non-normally distributed outcome variables (BMI and purchase data) were inverse normalized prior to analysis. Breakfast-, lunch-, and dinner-skipping variables from surveys were dichotomized to daily eaters (never skip) and skippers (skip 1 or more meal per week). Breakfast, lunch, and dinner "prepared at home" variables were dichotomized to fewer than 3 days of home meals per week or 3 or more days of home meals per week. Genetic score quartiles (e.g., Q1 = lowest genetic risk, Q4 = highest genetic risk) were generated based on the population distribution, with the highest quartile representing the more adverse phenotype (higher BMI). As enrollment was year-round, sine and cosine functions of the date of enrollment were used to adjust for seasonality in the participants' 3-month purchasing periods \[[@pmed.1003219.ref028]\]. The GPS was standardized to have a mean of 0 and a standard deviation of 1. Multivariable linear regression was used to test the association of each continuous, scaled PRS or GPS quartiles with BMI adjusted for age, sex, and 5 principal components of ancestry (identified by TRACE). In addition, multivariable linear or logistic regression was used to test genetic score associations with workplace purchases and survey-derived meal habits adjusted for age, sex, seasonality, and 5 principal components of ancestry. Differences across quartiles were evaluated for significance using a test for trend. We tested for statistical interaction between CNS-related and non-CNS-related results from stratified analyses (*P*~int~). Associations with purchases and meal habits were also repeated using continuous measures of the genetic scores. We present unadjusted (*P*) and false discovery rate--corrected *P* values (*P*~adj~) to account for multiple testing. In sensitivity analyses, we further adjusted for job type (administrative/service, craft/technicians, management/professionals, MDs/PhDs), education level (high school/some college, college degree, graduate degree), current smoking status, and physical activity level (measured with the International Physical Activity Questionnaire \[[@pmed.1003219.ref029]\] at the baseline visit). All genetic analyses were conducted in R version 3.6.2 (2019 December 12), and associations were considered significant at *P* \< 0.05.

Results {#sec016}
=======

Genetic analyses were restricted to 397 unrelated participants of European ancestry with high-quality genetic data in the "ChooseWell 365" study (**[Table 1](#pmed.1003219.t001){ref-type="table"}**, **[S1 Fig](#pmed.1003219.s008){ref-type="supplementary-material"}**). The mean age of participants included in this analysis was 44.9 years, and 80.9% were female. The medians (ranges) for the number of BMI-increasing alleles observed were 90 (70--105) for BMI~97~, 57 (42--70) for BMI~CNS~, and 33 (22--44) for BMI~non-CNS~ (**[S2 Fig](#pmed.1003219.s009){ref-type="supplementary-material"}**).

10.1371/journal.pmed.1003219.t001

###### General characteristics of "ChooseWell 365" study participants of European ancestry (*n* = 397).

![](pmed.1003219.t001){#pmed.1003219.t001g}

  Characteristics                                             Mean (SD) or Percentage
  ----------------------------------------------------------- -------------------------
  Age, years                                                  44.9 (12.8)
  Sex, % female                                               80.9
  Body mass index, kg/m^2^                                    27.9 (6.1)
  Job type, %                                                 
      Administrative/service                                  9.1
      Craft/technicians                                       9.3
      Management/professionals                                71.3
      MDs/PhDs                                                10.3
  Education level, %                                          
      High school/some college                                8.1
      College degree                                          43.1
      Graduate degree                                         48.4
  Smoking status (% current)                                  2.5
  Physical activity[\*](#t001fn001){ref-type="table-fn"}, %   
      Low                                                     2.3
      Moderate                                                28.0
      High                                                    69.7
  Skips breakfast \>1 day/week, %                             41.3
  Skips lunch \>1 day/week, %                                 34.5
  Skips dinner \>1 day/week, %                                20.9
  Breakfast prepared at home ≥3 days/week, %                  28.7
  Lunch prepared at home ≥3 days/week, %                      9.6
  Dinner prepared at home ≥3 days/week, %                     54.9

**\***Physical activity measured with the International Physical Activity Questionnaire at the baseline visit.

Abbreviations: SD, standard deviation

The GPS (BMI~GPS~) accounted for 14.8% of variance in BMI. The 97 loci (BMI~97~) accounted for 2.2% of variance in BMI, consistent with earlier reports \[[@pmed.1003219.ref008]\], and the BMI~CNS~ and BMI~non-CNS~ accounted for 1.2% and 0.5% of the BMI variance, respectively. Of the 97 BMI loci, 56 signals showed a direction of association consistent with the discovery GWAS (binomial *P* = 0.03) (**[S1 Table](#pmed.1003219.s003){ref-type="supplementary-material"}**). Generally, higher quartiles of the genetic scores were consistently associated with higher BMI (**[Fig 1](#pmed.1003219.g001){ref-type="fig"}**). The highest quartile (Q4) of the BMI~GPS~ was associated with a 6.4-kg/m^2^-higher (95% confidence interval \[CI\] 4.8--8.0) BMI relative to the lowest quartile (Q1) (*P* = 2.1 × 10^−15^). By comparison, the highest quartiles of the BMI~97~, BMI~CNS~, and BMI~non-CNS~ PRS were associated with a 2.4-kg/m^2^-higher (95% CI 0.7--4.1; *P* = 0.01), 1.9-kg/m^2^-higher (95% CI 0.2--3.6; *P* = 0.10), and 1.9-kg/m^2^-higher (95% CI 0.2--3.6; *P* = 0.04) BMI relative to the lowest quartile, respectively.

![Association of BMI genetic scores with participants' BMI (in kg/m^2^) according to quartiles of genetic scores.\
Higher quartiles reflect more BMI-increasing alleles. y-Axis is difference in BMI (in kg/m^2^) compared with reference quartile (Q1) adjusted for age, sex, and 5 principal components of ancestry. Asterisks denote significant (i.e., *P* \< 0.05) difference between quartile and Q1. The BMI~GPS~ is a GPS comprising 36,172 BMI-increasing risk alleles across the entire genome. The BMI~97~ PRS is restricted to 97 previously identified BMI variants at the genome-wide threshold \[[@pmed.1003219.ref008]\]. Based on the biological functions of genes in or near the 97 previously identified BMI loci, the BMI~CNS~ PRS and BMI~non-CNS~ PRS comprise 54 variants previously classified as CNS-related and 43 variants previously classified as non-CNS-related, respectively \[[@pmed.1003219.ref008]\]. For interpretation purposes, difference in BMI is derived from models in which BMI is untransformed, whereas *P* values are derived from models in which BMI is inverse normalized. BMI, body mass index; CNS, central nervous system; GPS, genome-wide polygenic score; OR, odds ratio; PRS, polygenic risk score.](pmed.1003219.g001){#pmed.1003219.g001}

**[Fig 2](#pmed.1003219.g002){ref-type="fig"}** shows associations between the BMI~GPS~ and the BMI~97~ genetic scores and workplace purchases (quality, quantity, and timing). The highest quartile of the BMI~GPS~ was associated with a lower Healthy Purchasing Score relative to the lowest quartile of the BMI~GPS~ (−4.8 percentage points \[95% CI −8.6 to −1.0\]; *P* = 0.02). The highest quartile of the BMI~GPS~ was also associated with purchasing more food items over the 3-month period (14.4 more items \[95% CI −0.1 to 29.0\]; *P* = 0.03) and with purchasing breakfast later (15.0 minutes later \[95% CI 1.5--28.5\]; *P* = 0.03) than the lowest quartile of BMI~GPS~. There were no significant associations between the BMI~97~ and workplace food purchases. **[Fig 3](#pmed.1003219.g003){ref-type="fig"}** shows associations between purchases and BMI~CNS~ and BMI~non-CNS~ risk scores. Significant heterogeneity between CNS and non-CNS was observed for the associations for total purchases (*P*~int~ = 0.02), food purchases (*P*~int~ = 0.03), and breakfast timing (*P*~int~ = 0.04). Relative to the lowest quartile, the highest BMI~CNS~ quartile was associated with fewer total (−18.5 items \[95% CI −38.4 to 1.4\]; *P* = 0.04) and food items (−12.6 food items \[95% CI −27.2 to 2.0\]; *P* = 0.04) purchased at work, and the highest BMI~non-CNS~ quartile was associated with purchasing breakfast later than the lowest quartile (17.9 minutes later \[95% CI 4.5--31.3\]; *P* = 0.01).

![BMI genetic scores associations with quality, quantity, and timing of workplace purchases.\
Association results are adjusted betas reflecting difference in Healthy Purchasing Score (percentage), items purchased (units over 3-month period), or timing (in minutes) between highest (Q4) and lowest (Q1, reference) quartile of BMI genetic scores adjusted for age, sex, seasonality, and 5 principal components of ancestry. Higher purchasing score = healthier purchases (0%--100%). For interpretation purposes, adjusted betas are from models in which outcomes are untransformed, whereas *P* values are derived from models in which outcomes are inverse normalized. *P* values are unadjusted for multiple testing, and false discovery rate--corrected *P* values (*P*~adj~) are presented in [S2 Table](#pmed.1003219.s004){ref-type="supplementary-material"}. BMI, body mass index; CI, confidence interval; GPS, genome-wide polygenic score.](pmed.1003219.g002){#pmed.1003219.g002}

![BMI~CNS~ and BMI~non-CNS~ genetic scores associations with quality, quantity, and timing of workplace purchases.\
Association results are adjusted betas reflecting difference in Healthy Purchasing Score (percentage), items purchased (units over 3-month period), or timing (in minutes) between highest (Q4) and lowest (Q1, reference) quartile of BMI genetic scores adjusted for age, sex, seasonality, and 5 principal components of ancestry. Higher purchasing score = healthier purchases (0%--100%). For interpretation purposes, adjusted betas are from models in which outcomes are untransformed, whereas *P* values are derived from models in which outcomes are inverse normalized. *P* values are unadjusted for multiple testing, and false discovery rate--corrected *P* values (*P*~adj~) are presented in [S2 Table](#pmed.1003219.s004){ref-type="supplementary-material"}. Based on the biological functions of genes in or near the 97 previously identified BMI loci, the BMI~CNS~ PRS and BMI~non-CNS~ PRS comprise 54 variants previously classified as CNS-related and 43 variants previously classified as non-CNS-related, respectively. BMI, body mass index; CI, confidence interval; CNS, central nervous system; GPS, genome-wide polygenic score; int, interaction; PRS, polygenic risk score.](pmed.1003219.g003){#pmed.1003219.g003}

Associations between the BMI genetic scores and self-reported meal skipping or meals prepared at home are demonstrated in **[Fig 4](#pmed.1003219.g004){ref-type="fig"}** and **[Fig 5](#pmed.1003219.g005){ref-type="fig"}**. Higher BMI~GPS~ was associated with lower odds of preparing dinner at home (Q4 odds ratio \[OR\] = 0.3 \[95% CI 0.1--0.9\]; *P* = 0.03), and no significant associations between the BMI~97~ genetic scores and meal skipping or meals prepared at home were observed (**[Fig 4](#pmed.1003219.g004){ref-type="fig"}**). In addition, BMI~non-CNS~ was associated with higher odds of skipping breakfast (Q4 OR = 2.0 \[95% CI 1.1--3.7\]; *P* = 0.03) and lower odds of preparing breakfast (Q4 OR = 0.5 \[0.3--1.0\]; *P* = 0.04) or lunch (Q4 OR = 0.4 \[0.2--0.8\]; *P* = 0.01) at home, with significant heterogeneity between CNS and non-CNS associations observed for preparing lunch at home only (*P*~int~ = 0.004) (**[Fig 5](#pmed.1003219.g005){ref-type="fig"}**).

![BMI genetic scores and self-reported meal skipping and meals prepared at home.\
Association results are adjusted odds ratio comparing highest (Q4) with lowest (Q1) quartile of BMI genetic scores adjusted for age, sex, seasonality, and 5 principal components of ancestry. Odds ratio \>1 indicates more meal skipping or more meals prepared at home. *P* values are unadjusted for multiple testing, and false discovery rate--corrected *P* values (*P*~adj~) are presented in [S2 Table](#pmed.1003219.s004){ref-type="supplementary-material"}. BMI, body mass index; CI, confidence interval; GPS, genome-wide polygenic score.](pmed.1003219.g004){#pmed.1003219.g004}

![BMI~CNS~ and BMI~non-CNS~ genetic scores and self-reported meal skipping and meals prepared at home.\
Association results are adjusted odds ratio comparing highest (Q4) with lowest (Q1) quartile of BMI genetic scores adjusted for age, sex, seasonality, and 5 principal components of ancestry. Odds ratio \>1 indicates more meal skipping or more meals prepared at home. *P* values are unadjusted for multiple testing, and false discovery rate--corrected *P* values (*P*~adj~) are presented in [S2 Table](#pmed.1003219.s004){ref-type="supplementary-material"}. BMI, body mass index; CI, confidence interval; CNS, central nervous system; GPS, genome-wide polygenic score; int, interaction.](pmed.1003219.g005){#pmed.1003219.g005}

Accounting for multiple testing resulted in *P*~adj~ greater than 0.05 for all findings (**[S2 Table](#pmed.1003219.s004){ref-type="supplementary-material"}**). In sensitivity analyses, results were similar when BMI genetic scores were expressed as continuous measures (**[S3 Table](#pmed.1003219.s005){ref-type="supplementary-material"}**); when these models were further adjusted for job type, education level, smoking status, and physical activity level in sensitivity analyses (**[S4 Table](#pmed.1003219.s006){ref-type="supplementary-material"}**); and when the BMI~GPS~ was calculated using other *P* value thresholds (**[S5 Table](#pmed.1003219.s007){ref-type="supplementary-material"}**).

Discussion {#sec017}
==========

In this study, we used objective, real-time food purchasing data to investigate the association of food choice behaviors with genetic risk for obesity. Using genetic risk scores derived with variants from a previous BMI GWAS meta-analysis, we found evidence that employees' genetic risk was associated with the quality, quantity, and timing of the food they purchased at work. Higher genetic risk was associated with several workplace food choice behaviors that may contribute to weight gain and obesity, including purchasing less healthy food; purchasing larger quantities of food; purchasing meals at later times; skipping breakfast; and being less likely to prepare meals at home. Prior research has demonstrated that lifestyle modification may attenuate genetic susceptibility to obesity and cardiometabolic risk \[[@pmed.1003219.ref011],[@pmed.1003219.ref030],[@pmed.1003219.ref031]\], and therefore our preliminary findings may have important implications for tailoring health-promotion and workplace wellness programs in the future.

Overall, BMI~GPS~ had the strongest associations with BMI and food choice behaviors. Higher BMI~GPS~ was associated with a lower Healthy Purchasing Score, a measure of the dietary quality of workplace food that has been correlated with overall dietary quality, as measured by 24-hour dietary recalls \[[@pmed.1003219.ref016]\]. The reasons for associations between higher genetic risk and purchasing more unhealthy foods at work are likely multifactorial and may include individual preferences for less healthy foods (e.g., foods high in saturated fat or sugar) \[[@pmed.1003219.ref015]\], impulsive behavior \[[@pmed.1003219.ref032]\], and vulnerability to unhealthy cues in the food environment \[[@pmed.1003219.ref033]\]. These associations are consistent with prior studies demonstrating that higher numbers of *FTO* obesity-related risk alleles were associated with more eating episodes per day, higher calories consumed at lunch, and stronger responses to food cues \[[@pmed.1003219.ref014],[@pmed.1003219.ref034],[@pmed.1003219.ref035]\]. Other loci have established roles in anorexigenic and orexigenic signaling pathways (*BDNF*) \[[@pmed.1003219.ref036]\], nutrient preference such as carbohydrate (*RARB*) \[[@pmed.1003219.ref006]\] and fat (*ADH1B*) \[[@pmed.1003219.ref037]\], and energy homeostasis (*MTCH2*) \[[@pmed.1003219.ref038]\]. Our findings, however, do not implicate specific genes or mechanisms, and the precise biological role of most BMI loci remain to be elucidated \[[@pmed.1003219.ref011]\].

Higher BMI~GPS~ was also associated with purchasing more food items at work and being less likely to prepare dinner at home, a behavior previously associated with obesity in adults \[[@pmed.1003219.ref039]\]. Lastly, the association between higher genetic risk and later breakfast purchases corroborates earlier nongenetic epidemiological findings between higher BMI and later food intake \[[@pmed.1003219.ref040],[@pmed.1003219.ref041]\]. The greater number of significant associations observed for the BMI~GPS~ relative to the BMI~97~ may be due to the fact that the BMI~GPS~ explained 6 times more BMI variance than the BMI~97~, resulting in a more robust genetic risk score and possibly capturing more of the underlying biology for BMI. Several findings for the BMI~97~ were consistent in direction with the BMI~GPS~ and may require a larger sample size before significant associations are detected. Collectively, these findings suggest that genetic risk for obesity may play a role in vulnerability to food behaviors that contribute to weight gain.

To further explore the association of genetic risk for obesity and food choice, we examined differences by the 97 genetic variants for BMI that are enriched for expression in regions of the CNS compared with the remaining variants that are expressed in other tissues with non-CNS functions. Prior research provided evidence indicating possible differential effects of these subsets, with BMI~CNS~ having a stronger interaction with dietary quality on BMI than BMI~non-CNS~ \[[@pmed.1003219.ref011]\]. In our study, we observed subset differences in the quantity of food purchased at work, with higher BMI~CNS~ associated with purchasing fewer food items at work and higher BMI~non-CNS~ trending toward purchasing more food items at work. Higher BMI~non-CNS~ was associated with purchasing breakfast at a later time, skipping breakfast, and not preparing breakfast or lunch at home, but BMI~CNS~ was not associated with any of these factors. Contrary to our initial hypothesis, our results suggest that BMI~non-CNS~ had a stronger association with employees' food choice behaviors that could lead to weight gain than BMI~CNS~. Given that the workplace food environment in this study utilized cues to promote healthier eating (i.e., traffic-light labels), it is possible that these cues may have attenuated the unhealthy food choice behaviors of employees with higher BMI~CNS~ but did not interact with behaviors of employees with higher BMI~non-CNS~. Although these preliminary findings will need to be confirmed in larger samples, our results may have implications for tailoring interventions for subgroups of individuals, and insights could be leveraged to unravel and classify subtypes of BMI genetic risk, as has been conducted for other diseases such as diabetes \[[@pmed.1003219.ref042]\].

A major strength of this study is the objective and comprehensive assessment of workplace food purchases derived from 3 months of cafeteria sales data. These measures were not prone to misreporting or social desirability biases, in contrast to many prior studies in the field. Our approach also enabled a multidimensional capture of food choice behavior, including timing. Furthermore, the relevant self-reported dietary behavior provided results that were complementary to the cafeteria purchasing findings.

There are also important limitations. Although the cafeteria systems provided objective data, food purchases may not have reflected actual food consumption that may have been influenced by work shift schedules and cafeteria hours. The BMI~CNS~ and BMI~non-CNS~ designations were limited to the 97 previously characterized BMI genetic variants, but additional variants may be missing from these genetic scores. We primarily present *P* values unadjusted for multiple testing because of our modest sample size and because the BMI genetic risk scores and the outcomes tested were not independent. Therefore, we acknowledge that individual "significant" findings should be interpreted with caution, since accounting for multiple comparisons led to nonsignificant *P* values, and that larger samples are necessary to verify our findings. Although the types of data we collected suggest we could infer potential causal links using mendelian randomization analyses, our sample size is too small for such an approach. Selection bias was possible as a result of inclusion and exclusion criteria for the randomized trial in addition to the criteria for this analysis, such as non-European ancestry (restricted to avoid population stratification issues). Also, despite our covariate adjustment, we recognize that a general weakness of observational studies is a risk of bias due to residual confounding. Finally, our sample consisted of a relatively small number of healthy working adults at a large urban hospital who had volunteered to enroll in a health-promotion study, which may limit generalizability of our findings to other working populations and rural or non-employed people.

In conclusion, this study identified associations between obesity genetic risk scores and food choice behaviors, suggesting that the genetic risk for obesity may play a role in vulnerability to food behaviors that are relevant for the development of obesity. Our findings demonstrated that higher genetic risk for BMI was associated with workplace food choice behaviors that may contribute to weight gain. Prior research has shown that healthy lifestyle behaviors, including dietary intake, can attenuate weight gain and cardiovascular disease in those at high genetic risk \[[@pmed.1003219.ref011],[@pmed.1003219.ref030],[@pmed.1003219.ref031]\]. Therefore, understanding genetic predisposition to certain food choice behaviors that contribute to cardiometabolic disease could inform interventions that are tailored to changing individuals' dietary habits.
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Dear Dr. Dashti,

Thank you very much for submitting your manuscript \"Association of genetic risk for obesity with the quality, quantity, and timing of workplace food purchases\" (PMEDICINE-D-20-00219R1) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

\[LINK\]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers\' and editors\' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: <http://journals.plos.org/plosmedicine/s/figures>. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <PLOSMedicine@plos.org>.

We expect to receive your revised manuscript by May 29 2020 11:59PM. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <http://journals.plos.org/plosmedicine/s/competing-interests>.

Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \"Submissions Needing Revision\" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Adya Misra, PhD

Senior Editor
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Please revise your title according to PLOS Medicine\'s style. Your title must be nondeclarative and not a question. It should begin with main concept if possible. \"Effect of\" should be used only if causality can be inferred, i.e., for an RCT. Please place the study design (\"A randomized controlled trial,\" \"A retrospective study,\" \"A modelling study,\" etc.) in the subtitle (ie, after a colon).

Abstract

Aim and study design should be clearly stated in the background and methods section respectively

Please provide brief participant demographics and when the study took place

Please provide participant numbers

Please provide precise p-values, except when p\<0.001

The last sentence of the methods and findings section must highlight a limitation of your study design or methodology

Abstract Conclusions:

\* Please address the study implications without overreaching what can be concluded from the data; the phrase \"In this study, we observed \...\" may be useful.

\* Please interpret the study based on the results presented in the abstract, emphasizing what is new without overstating your conclusions.

\* Please avoid vague statements such as \"these results have major implications for policy/clinical care\". Mention only specific implications substantiated by the results.

\* Please avoid assertions of primacy (\"We report for the first time\....\")

Author summary

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

Prospective analysis plan

Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a\) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b\) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c\) In either case, changes in the analysis\-- including those made in response to peer review comments\-- should be identified as such in the Methods section of the paper, with rationale.

Introduction

Please conclude this section with a clearly outlined aim of your study

Methods

Please use the Methods heading instead of "subjects and methods".

Since this is a secondary analysis of an RCT, please do explicitly mention this in the abstract and methods sections

Results

Please provide precise p values

Line 310-311- we do not permit instances of data not shown, so please provide these data or remove this sentence

Please report your study according to the relevant guideline (<http://www.equator-network.org/>), perhaps STROBE/STREGA guideline, and include the completed checklist as Supporting Information. When completing the checklist, please use section and paragraph numbers, rather than page numbers. Please add the following statement, or similar, to the Methods: \"This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist).\" Please report your study according to the relevant guideline, which can be found here: <http://www.equator-network.org/>

Comments from the reviewers:

Reviewer \#1: The authors present a very interesting study that correlates genetic risk scores for BMI with food choices.

The genetic risk scores are generated in four different ways based on an existing GWAS, one genetic risk score is based on genome-wide data (GRS), while the other three scores are based on 97 genome-wide significant SNPs, which is further subdivided into 54 SNP related to the central nervous system and 43 SNPs which are not.

The design of the study is innovative and could provide important insights into how genetics influence human behaviour. The manuscript is well written and clear. Yet, I would appreciate if the authors could address my comments on the statistical analysis.

Major comments:

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

1\. Different results depending on the risk score used: How do the authors explain the stark difference in results between the GRS and 97 SNP risk scores as shown in Figure 2? While there are suggestive findings for GRS, the results for the 97 SNP risk score are Null.

2\. Overfitting of the genome-wide PRS: How robust are the results with respect to different p-value cut-offs of the genome-wide PRS? A p-value threshold of 0.19 seems rather lenient and arbitrary. Did the authors perform any more sensitivity analysis on this p-value threshold? May the tuning of the threshold parameter in the actual dataset induce overfitting?

3\. Multiple testing: Why did the study not adjust for multiple testing? In my opinion this study would require to adjust at least for the number of outcomes examined.

4\. Power calculation: Did the authors perform a power calculation prior to the study? Is the study well-powered to detect differences in food choice based on genetic risk?

5\. How representative is the sample? Supplementary Table 1 states that 80% of the participants are women, 70% have high physical activity and the average BMI is 27.9. What were the selection criteria for enrolling participants in the Choosewell study? Please discuss if there is potential selection bias in the study due to the participants not being selected at random but volunteering.

6\. Quartiles: Why did the authors decide to summarise the polygenic scores into quartiles and present results as the comparison between highest and lowest quartile? How do the results look like when including the exact scores as quantitative predictors into the model?

Minor comments:

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

\- Supplementary Figure 1. Please put \"\" around \"ChooseWell 365\", otherwise this may read as 365 study participants.

\- Supplementary Table 2. Explain \"highly expressed in the CNS\" in the legend.

Reviewer \#2: The authors present a secondary analysis(?) of an impressive trial, where participants health behaviour manipulated. The dataset is rich as objective food purchases have been measured, along with genetics. I would be very intrigued to read analysis of the phenotypic BMI in relation to the objective eating study variables. The PGS just seems to serve as a fancy method, but I think using PGS is an overkill - it makes associations very small and ultimately does not deliver any extra interpretative value.

The study seems as a secondary analysis, as although the study is a trial, the manipulation is not being analysed. It would be helpful to have a reference to the paper analysing primary outcomes of the study, if available. The clinical trial outlines a moderating role of the PGS. This does not seem to be tested here. Please outline clearly, whether you followed the clinical trials protocol in this analysis or conducted exploratory additional analyses. Both approaches are ok, this just needs to be clear.

The study\'s goals fall short likely due to smallish sample size for these goals. This is expemplified by the use of quartiles throughout the paper, which highlight associations that likely do not emerge when using PGS-s as linear predictors. This approach has been previously critiqued in relation to polygenic scores. See this blog for accessible overview and further materials. <https://discourse.datamethods.org/t/discussion-of-polygenic-prediction-of-weight-and-obesity-trajectories-from-birth-to-adulthood/1585> . If the authors wish to use quartiles, they should justify their choice in relation to this critique.

I invite authors to think through, what is the message and scientific question they want to deliver. If the goal is to understand how obesity influences food choices and reactiveness to the trial, then I would just use phenotypic obesity. This allows using a bigger sample, and also having bigger statistical effects. I would be very interested in learning the phenotypic results!

Generally speaking, BMI_PGS-phenotype associations reproduce known BMI_phenotype-phenotype associations. So you could just study phenotypic associations and conclude that this is likely how genetic BMI plays out. Perhaps you could try reproducing the strongest phenotypic BMI- eating associations with a BMIpgs?

If you want to make claims between BMIcns- and BMInon-cns, you need to test the statisical difference in effect sizes. <http://comparingcorrelations.org/>

Polygenic scores can also be used in certain conditions to infer causality. But I think that you need a larger sample size to do this kind of research.
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Reviewer \#3: This study addresses a more relevant aspect in the knowledge of determining factors of obesity that has also been scarcely described as is the choice of food.The work is well written and the results presented, below with some comments:

1.The authors mention the fact that is in workplace, it could be also interesting if they could discuss about what kind of food is available in those cafeteria and if that could be a bias

2.The authors mention that the collection was made three months retrospectively, is that because it was part of another study or why it is measured retrospectively?. In that sense the authors calculated the average?

3.It would be interesting if the authors could characterize the types of food available in the cafeteria, in addition to saying the traffic lights.

4.Although in complementary material they indicate the genes evaluated, it is interesting that in the discussion they could deepen into this and how some genes could effectively modulate aspects of food choice, put it in more concrete terms on the mechanism

Any attachments provided with reviews can be seen via the following link:
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Dear Dr. Dashti,

Thank you very much for re-submitting your manuscript \"Genetic risk for obesity and the quality, quantity, and timing of workplace food purchases: a cohort study\" (PMEDICINE-D-20-00219R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Jun 11 2020 11:59PM.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)
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Requests from Editors:

Suggest title is tempered as you are not directly measuring genetic risk? In addition, the study descriptor might be better as 'a secondary analysis from the ChooseWell 365 randomised trial'.

Please provide a table with demographic information of participants

Please consider revising "influencing" to perhaps "associated with" as this is an observational study "We also assessed whether higher CNS-related obesity genetic risk that may be more likely to influence food behavioural choices than the non-CNS component". The same goes for where you mention "causal in pathway". I don't think the study design or results allow this extrapolation, so please use more cautious language throughout.

It appears that your STROBE checklist was not included in the revised manuscript and it was not called out in the methods section. Please do so, as requested previously. We ask that you don't use line or page numbers as these are likely to change during publication

In the methods, in addition to simply mentioning that you had a prospective analysis plan, please provide this analysis plan as an SI file and also provide a call out to the file in the methods section. As stated previously "If a prospective analysis plan (from your funding proposal, IRB or other ethics

committee submission, study protocol, or other planning document written

before analyzing the data) was used in designing the study, please include the

relevant prospectively written document with your revised manuscript as a

Supporting Information file to be published alongside your study, and cite it in

the Methods section. A legend for this file should be included at the end of your manuscript".

Please add unaccounted confounding as a limitation in your discussion, as there are several confounders linked to food choice and not all can be measured in an observational setting.

Comments from Reviewers:

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003219.r005
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18 Jun 2020

Dear Dr. Dashti,

On behalf of my colleagues and the academic editor, Dr. Sanjay Basu, I am delighted to inform you that your manuscript entitled \"Polygenic risk score for obesity and the quality, quantity, and timing of workplace food purchases: a secondary analysis from the ChooseWell 365 randomised trial\" (PMEDICINE-D-20-00219R3) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: The authors have declared that no competing interests exist.
